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AMPK AMP-activated protein kinase 
SDH succinate dehydrogenase 
PGC-1α peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
Cycs cytochrome c 
MEF2A myocyte enhancer factor 2A 
GLUT4 glucose transporter 4 
MyHC-I myosin heavy chain 7 
MuRF1 Muscle RING-finger 1 
Gas gastrocnemius 
EDL extensor digitorum longus 
WAT white adipose tissue 
FFA free fatty acids 













































There is no doubt that the rapid growth in aging population becomes a major global 
concern, and this trend is expected to continue with a concurrent increase in age-related 
diseases [1]. Aging, as an inevitable process, could lead to physiological functional 
decline in metabolic, respiratory, exercise capacity associated with loss of skeletal muscle 
mass and strength, obesity, and many metabolic diseases, such as type 2 diabetes [2-4]. 
Maximal oxygen uptake (VO2max) declines with age, possibly due to a diminished 
capacity to deliver and extract O2 during exercise, in humans [5, 6]. In skeletal muscle, 
aging process contributes to muscle weakness and increased fatigability [7], decline of 
skeletal muscle, mitochondrial function, and physical activity [8], leading to impaired 
mobility and loss of independence in individuals [9]. Dawson reported that significant 
age-related declines in taurine content were observed in a number of tissues with 
advancing age [10]. So we speculate that taurine supplementation might have anti-aging 
effects on these age-related changes. 
Taurine (2-aminoethanesulfonic acid) is a free amino acid found abundantly in 
mammalian tissues [11], particularly in excitable tissues such as the brain, cardiac, and 
skeletal muscles [12,13]. From the perspective of food nutrition, taurine abounds in 
seafood and poultry [14]. The most primary role of taurine is anti-fatigue. For this reason, 
taurine is added to various energy drinks, generally at a concentration of ~1000 mg per 
250 mL serving [15,16]. As an endogenous amino acid, taurine serves many physiological 
and pharmacological roles including: bile acids conjugation [17], plasma membrane 
stabilization [18], osmoregulation [19], neuromodulation [20], neurotransmission [21], 
and anti-oxidation [22]. It was reported that taurine supplementation could improve 
exercise performance and duration, up-regulated physical endurance, and maintained the 
concentration of taurine in the muscle [23,24]. Taurine levels in muscle decreased after 
4 
 
exercise, but taurine supplementation has effects on maintaining taurine level and 
improving exercise performance [25,26]. Taurine is essential for skeletal muscle function. 
Warskulat et al. (2004) found that taurine deficiency in taurine transporter knockout 
(taut−/−) mice reduced the functioning of skeletal muscle [27]. Additionally, taurine 
depletion accelerates skeletal muscle aging and leads to early death in mice [28]. Chronic 
administration of taurine to aged male Wistar rats improved the electrical and contractile 
properties of their skeletal muscle fibers [29]. However, the anti-aging effects of taurine 
and mechanism have not been clarified before. Given that taurine is associated with the 
function of skeletal muscle and exercise capacity as mentioned above, it is hypothesized 
that taurine might have anti-aging effects on age-related changes, especially skeletal 
muscle function.  
In this study, the present author attempted to investigate age-related changes, 
including VO2, spontaneous locomotor activity, and gene expression in skeletal muscle 
of aged rats (the detail shown in Chapter Ⅱ), which provide a potential perspective for 
taurine anti-aging research. In addition, although there are numerous researches of taurine 
effects, most of them focused on supplementation of relatively high concentrations of 
taurine, or short-term taurine supplementation models. The research of taurine effects of 
a relatively low dose, long-term administration is limited. In order to know the effects of 
low dose of taurine supplementation, just like daily food intake, the present author 
attempted to examine the anti-aging effects of long-term (5 months) administration of 0.5%  
or 1% taurine on age-related changes (the detail shown in Chapter Ⅲ) in VO2 
consumption, spontaneous locomotor activity, skeletal muscle function. The evidence of 
















Age-related changes in energy metabolism and skeletal muscle function 


















Aging is an unavoidable process that causes a decline in metabolic, respiratory, and 
exercise functions, which are associated with loss of skeletal muscle mass and strength, 
mitochondrial dysfunction, and metabolic diseases [2-4, 30]. Aging decreases skeletal 
muscle and mitochondrial function and leads to a reduction in their functional capacity, 
which results in a decline in physical activity [7, 8]. Evidence shows that maximal oxygen 
uptake (VO2max) declines with age [5, 31-32]. In one study, it was found that VO2max 
was 36% lower in master runners than in young runners, possibly as a consequence of 
diminished capacity to deliver and extract O2 during exercise [6]. Conley et al. [33] 
reported a 50% reduction in oxidative capacity in older human subjects compared to 
young subjects, due to reduced mitochondrial volume and reduced mitochondrial function. 
Previous studies reported that the level of peroxisome proliferator-activated receptor 
gamma coactivator 1-alpha (PGC-1α), which is a transcriptional coactivator that regulates 
the genes involved in energy metabolism and is the primary regulator of mitochondrial 
functions [34-36], in skeletal muscle decreased with age [37]. Aging process is also 
associated with dysregulation of lipid metabolism. Honma showed that the weight of 
white adipose tissue (WAT) and levels of liver triacylglycerol, plasma free fatty acids 
(FFA), and plasma insulin showed an increase with aging in SAMP10 mice [38]. Muscle 
RING-finger 1 (MuRF1), which is highly induced in atrophying muscle, may play an 
important role in the breakdown of myofibrillar proteins [39, 40]. Atrogin-1 mRNA 
increases 8 to 40-fold in atrophy study, and this increase precedes the onset of muscle 
weight loss [39, 41]. In Chapter Ⅱ, age-related changes was investigated, including VO2, 
spontaneous locomotor activity, tissue weight, blood biochemical index, and gene 




MATERIALS AND METHODS 
 
Materials 
Formalin, 2-mercaptoethanol, 1% eosin Y solution, and commercial assay kit for 
free fatty acid (FFA) (NEFA C-Test Wako), cholesterol (Cholesterol E-Test Wako) and 
Oil-Red O were purchased from FUJIFILM Wako Pure Chemical Corporation (Osaka, 
Japan). Ethanol and nitro blue tetrazolium were purchased from Sigma-Aldrich (St. Louis, 
MO, USA), and hematoxylin from Merck KGaA (Darmstadt, Germany). Mount-Quick 
and Mount-Quick aqueous mounting media were purchased from Daido Sangyo Co., Ltd 
(Tokyo, Japan). Sepasol-RNA I Super G and sodium succinate were purchased from 
Nacalai Tesque (Kyoto, Japan). RNase inhibitor, ReverTra Ace® qPCR (quantitative 
polymerase chain reaction) Master Mix, and gDNA (genomic DNA) remover kit were 
purchased from TOYOBO Co., Ltd. (Osaka, Japan). KAPA SYBR® FAST qPCR kit was 
purchased from Kapa Biosystems (Wilmington, MA, USA). 
 
Animal experiments 
The care and use of the animals in this study followed the guidelines of Okayama 
Prefectural University and the laws and notifications of the Japanese government. All 
animal experiments were approved by the Animal Care and Use Committee of Okayama 
Prefectural University (protocol number 27-3). Male SD rats aged 32 weeks (n=4-15) 
were obtained from Charles River Laboratories Japan, Inc. (Yokohama, Japan). They 
were housed individually in an air-conditioned room at 25 °C with an alternating 12 h 
light/dark cycle (light, 8:00-20:00). All rats were allowed free access to commercial food 
(CE-2, CLEA Japan, Inc., Tokyo, Japan) and water. Food intake and body weight were 
measured daily. Respiratory metabolism was measured with VO2 and CO2 generation 
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volumes, using a metabolism measuring system (MK-5000, Muromachi Kikai, Tokyo, 
Japan), and spontaneous locomotor activity was measured using an infrared sensor 
(SUPERMEX SENSOR PYS-001, Muromachi Kikai, Tokyo, Japan). Each rat was kept 
in a sealed chamber for 24 h at 25 °C. The airflow was 3.0 L/min. The animals had free 
access to water and food. At the age of 32, 85, and 92 weeks, the rats were anesthetized 
by an intraperitoneal injection of pentobarbital sodium (100 μL/100 g of body weight). 
Tissue were collected and stored at -80 °C until subsequent measurements. Blood samples 
were collected in heparinized tubes and centrifuged at 3,000 × g and 4 °C for 10 min and 
plasma was obtained. FFA and cholesterol in plasma were determined by commercial kit. 
 
Histological analysis 
The soleus muscle was cut into 10 μm sections using a Leica CM3050 S cryostat 
(Leica Microsystems, Wetzlar, Germany) at -20 °C and fixed in 10% (v/v) formalin. The 
sections were stained with hematoxylin and eosin (H&E) and mounted in Mount-Quick 
medium. The sections were stained with Oil-Red O and mounted in Mount-Quick 
Aqueous medium. For succinate dehydrogenase (SDH) staining, the soleus sections were 
air-dried at room temperature and incubated in a solution consisting of 50 mM phosphate 
buffer (6 mM potassium dihydrogenphosphate and 44 mM disodium hydrogenphosphate), 
50 mM sodium succinate, and 0.5 mg/mL nitro blue tetrazolium at 37 °C for 40 min. The 
sections were washed in double distilled H2O for 3 min and mounted in Mount-Quick 
aqueous mounting medium. Images were captured with a CCD camera (Olympus Optical, 





Total RNA was isolated from frozen tissue with Sepasol-RNA I Super G. RNase inhibitor 
was added according to the manufacturer’s instructions. Total RNA was measured and 
cDNA was prepared using the ReverTra Ace® qPCR Master Mix and gDNA remover kit. 
After RNA extraction with Sepasol RNA I Super G, DNA was obtained by 250 μl back 
extraction buffer (4 M guanidine thiocyanate; 50 mM sodium citrate; 1 M Tris, pH 8.0) 
into the phenol phase and interphase. qRT-PCR was performed in a StepOnePlus real-
time PCR system (Applied Biosystems, CA, USA) using the KAPA SYBR® FAST qPCR 
kit, to evaluate specific mRNA content. Data were normalized to β-actin mRNA, and the 
expression levels were compared to the mRNA expression values in rats aged 32 weeks. 
The qRT-PCR primers are listed in Table 1.  
 
Statistical analysis 
Data are presented as mean ± standard error (SE). Results were analyzed using 
Student’s T-test or subjected to one-way analysis of variance (ANOVA) followed by the 














Table 1. Primers used for PCR. 
 
Gene Direction Primer sequence 
β-actin (Actb)  forward 5′-GGAGATTACTGCCCTGGCTCCTA-3′ 
 reverse 5′-GACTCATGTACTCCTGCTTGCTG-3′ 
MyHC-I (Myh7) forward 5′-AGAGGAAGACAGGAAGAACCTAC-3′ 
 reverse 5′-GGCTTCACAGGCATCCTTAG-3′ 
PGC-1α (Ppargc1α) forward 5′-GACCCCAGAGTCACCAAATGA-3′ 
 reverse 5′-GGCCTGCAGTTCCAGAGAGT-3′ 
Cycs (Cycs) forward 5′-AGCGGGACGTCTCCCTAAGA-3′ 
 reverse 5′-CTTCCGCCCAAACAGACCA-3′ 
SDH (sdha) forward 5′-TGGGGCGACTCGTGGCTTTC-3′ 
 reverse 5′-ATCTCCAGTTGTCCTCTTCCA-3′ 
MuRF1 (Trim63) forward 5′-CGACTCCTGCCGAGTGACC-3′ 
 reverse 5′-GCGTCAAACTTGTGGCTCAG-3′ 
Atrogin-1 (Fbxo32) forward 5′-GAACAGCAAAACCAAAACTCAGTA′ 
 reverse 5′-CTCCTTAGTAGTACTCCCTTTGTGAA-3′ 
MtND1 (mt-Nd1) forward 5′-CTCCCTATTCGGAGCCCTAC-3′ 







Age-related changes of body weight gain, respiratory metabolism, and spontaneous 
locomotor activity 
To see the effect of aging process on the respiratory metabolism and spontaneous 
activity, VO2 and spontaneous locomotor activity were measured for SD rats from 32 
weeks to 90 weeks of age. As rats aging, VO2 (mL/min/kg) and spontaneous locomotor 
activity (count/min) during the resting period, active period, and the whole day period 
significantly decreased continuously from age 52 weeks (52 w) to 90 weeks (90 w) 
compared with that at 32 weeks (32 w) (Fig 1A, B). The body weight gain (g) increased 
gradually as rats aging, from age 34 to 91 weeks (Fig 1C). 
 
Age-related changes of lipid accumulation 
As shown in Table 2, weight of WAT around the kidney increased significantly in 
the rats aged 85 weeks (38.8 ± 3.35 g/kg) and 92 weeks (38.3 ± 2.19 g/kg) compared to 
that in rats aged 32 weeks (19.4 ± 1.86 g/kg). The weight of WAT around the testicle 
increased, but not statistically significant, in rats aged 85 and 92 weeks, compared to that 
in rats aged 32 weeks. The mass of soleus muscle decreased significantly in rats aged 85 
weeks (0.47 ± 0.04 g/kg) and 92 weeks (0.50 ± 0.06 g/kg) compared to that in rats aged 
32 weeks (0.70 ± 0.03 g/kg). The mass of Gas muscle also decreased significantly in rats 
aged 85 weeks (5.00 ± 0.33 g/kg) and 92 weeks (5.62 ± 0.54 g/kg) compared to that in 
rats aged 32 weeks (8.89 ± 0.50 g/kg). As rats aged, the level of plasma FFA (mEq/L) 
increased significantly in rats aged 50 to 92 weeks compared to that in rats aged 32 weeks 
(Fig 2A). The level of plasma cholesterol (mg/dL) tended to increase in rats during the 
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aging process (Fig 2B). The results of H&E staining and Oil-Red O staining, age-related 
changes in the soleus muscle in SD rats, are shown in Fig 3. The tissue sections with Oil-
Red O staining in rats aged 85 weeks showed more lipid accumulation and it of 92 weeks 













Fig 1. VO2 in SD rats from 32 to 90 weeks of age in resting, active, and whole day periods 
(a). Spontaneous locomotor activity of SD rats from 32 to 90 weeks of age in the resting, 
active, and whole day periods (b). The resting period was 10:00 am–8:00 pm, active 
period was 8:00 pm–8:00 am, and the whole day period was from 10:00 am–8:00 am. 
Average body weight gain in SD rats from 34 to 91 weeks of age (c). Values shown 
represent means ± SE for 4–15 rats. *p <0.05, **p <0.01 statistically significant versus 
the value obtained at 32 weeks of age. Results were analyzed with one-way ANOVA 
followed by the Tukey–Kramer post hoc test for multiple comparisons 
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Table 2. Aging-related changes on tissue weight of WAT (kidney), WAT (testicle), soleus 
muscle and Gas muscle in SD rats at age 32, 85 and 92 weeks.  
 
g/kg-BW 32w 85w 92w 
WAT (kidney) 19.4 ± 1.86 a 38.8 ± 3.35 b 38.3 ± 2.19 b 
WAT (testicle) 20.9 ± 1.19 a 22.5 ± 1.48 a 25.1 ± 1.04 a 
Soleus 0.70 ± 0.03 a 0.47 ± 0.04 b 0.50 ± 0.06 b 
Gas 8.89 ± 0.50 a 5.00 ± 0.33 b 5.62 ± 0.54 b 
Values shown represent means ± SE of 3-7. Results were analyzed with one-way ANOVA 
followed by the Tukey-Kramer post hoc test for multiple comparisons. Groups without 














Fig 2. Age-related changes in plasma FFA and cholesterol in SD rats aged 32 to 92 weeks.  
(A) Plasma FFA level (mEq/L), (B) Plasma cholesterol level (mg/dL). The values shown 
represent mean ± SE of 3-12 rats. The results were analyzed with one-way ANOVA 
followed by the Tukey-Kramer post-hoc test for multiple comparisons. The groups 
















Fig 3. Age-related changes in H&E and Oil-Red O staining of soleus muscle of SD rats 












Fig 4. Age-related changes in mitochondrial function of soleus muscle.  
(A) Relative mitochondrial DNA level in soleus muscle. The results were analyzed with 
one-way ANOVA followed by the Tukey-Kramer post-hoc test for multiple comparisons. 
The groups without the same letter present a statistically significant difference (p<0.05). 
The values shown represent mean ± SE of 3-6 rats. (B) SDH staining of soleus muscle 















Fig 5. Age-related changes in relative mRNA expression levels of MyHC-I (Myh7), PGC-
1α (Ppargc1α), Cycs (Cycs), SDH (sdha), MuRF1 (Trim63), and Atrogin-1 (Fbxo32) in 
soleus muscle of SD rats aged 32, 85, and 92 weeks.  
The values shown represent mean ± SE of 3-6 rats. The results were analyzed with one-
way ANOVA followed by the Tukey-Kramer post-hoc test for multiple comparisons. The 
groups without the same letter present a statistically significant difference (p<0.05). 
 
Age-related changes of skeletal muscle function 
The relative mitochondrial DNA level were decreased significantly in the soleus 
muscle of rats aged 85 and 92 weeks compared to that of rats aged 32 weeks (Fig 4A). 
SDH staining of soleus muscle was performed to characterize mitochondrial enzyme 
function and myofiber oxidative capacity (19,20). From the results of SDH staining, the 
soleus muscle of rats aged 85 and 92 weeks showed a decrease in the positive staining 
level compared to that of rats aged 32 weeks (Fig 4B). With aging, mRNA expression of 
myosin heavy chain 7 (MyHC-I) (Myh7), PGC-1α (Ppargc1α), cytochrome c (Cycs) 
(Cycs), and SDH (sdha) decreased significantly in the soleus muscle of rats aged 85 and 
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92 weeks compared to that of rats aged 32 weeks (Fig 5). Expressions of MuRF1 (Trim63) 
and Atrogin-1 (Fbxo32) mRNA increased significantly in the soleus muscle of rats aged 






With the aging of rats, VO2 in the resting, active, and whole day periods continuously 
decreased significantly from the age of 52 to 90 weeks relative to that at the age of 32 
weeks (Fig 1A), suggesting that the aging process might contribute to a decline in O2 
consumption, which is indicated as a typical age-related change. Rivera also reported that 
VO2max was lower in master runners than in young runners because of a diminished 
capacity to deliver and extract O2 during exercise, in master runners [6]. In the same way, 
with aging, the spontaneous locomotor activity in the resting, active, and whole day 
periods continuously decreased significantly from age 52 to 90 weeks relative to that at 
age 32 weeks (Fig 1B). This indicates that the loss of spontaneous locomotor activity is 
an unavoidable phenomenon and a characteristic of the aging process. In a previous study 
by Conley et al, aged rats (24-27 months old) consistently presented lower spontaneous 
locomotor activity compared to young rats (3-6 months old), during the dark cycle (20:00-
8:00) [33]. In another study, aged F344 rats showed 75-80% reduction in locomotor 
activity compared to young rats [42], which is also consistent with the result in this study. 
Age-related muscle weakness and reduced aerobic capacity result not only in 
diminished physical performance, but also in metabolic disorders in humans [43, 44]. 
Reduced muscle mitochondrial function could contribute to age-related muscle 
dysfunction and reduced aerobic capacity [8]. In this study, it was observed that the 
relative mitochondrial DNA level was decreased significantly in the soleus muscle of rats 
aged 85 and 92 weeks compared to that of rats aged 32 weeks (Fig 4A). SDH activity is 
a performance for mitochondrial oxidative capacity [45, 46], and SDH staining results 
showed that mitochondrial oxidative capacity decreased in the soleus muscle of rats aged 
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85 and 92 weeks compared to that of rats aged 32 weeks (Fig 4B). Ermini et al. showed 
that SDH activity decreases in the muscles of old rats as compared to young rats [47]. 
Myosin heavy chain is an essential component of skeletal muscle and is associated with 
skeletal muscle contraction function [43, 48-49]. With advancing age, relative mRNA 
expression levels of PGC-1α, Cycs, and SDH decreased significantly in the soleus muscle 
of rats aged 85 and 92 weeks, compared to that of rats aged 32 weeks (Fig 5). PGC-1α 
plays a major role in metabolic regulation [34, 50], oxidative capacity [51], and regulation 
of respiration in skeletal muscle [52]. Dillon also showed that during aging, there is a 
decrease in PGC-1α expression in the heart and skeletal muscles [53]. Cycs is essential 
for energy production and mitochondrial respiration, as a component of the electron 
transport chain and as a mitochondrial marker protein [54, 55]. The results of this study 
showed that the aging process might contribute to age-related decline of mRNA 
expression involved in mitochondrial oxidative function. Atrogin-1 and MuRF-1 have 
been identified as important enzymes in muscle atrophy, and regulation of their 
expression has the potential to prevent or reverse muscle atrophy in patients with 
sarcopenia [56]. In this study, the relative mRNA expression levels of MuRF1 and 
Atrogin-1 were increased significantly in the soleus muscle of rats aged 85 and 92 weeks 
compared to that of rats aged 32 weeks. 
Aging is also associated with the dysregulation of lipid metabolism. In this study, 
the weight of WAT around the kidney was increased significantly and skeletal muscle 
mass was decreased significantly in rats aged 85 and 92 weeks compared to that in rats 
aged 32 weeks (Table 2). Consistently, previous research by Honma et al. found that the 
weight of WAT (epididymal, mesenteric, and perirenal) was increased significantly with 
aging in SAMP10 mice [38]. In this study, Oil-Red O staining results showed that lipid 
19 
 
accumulation was also increased in the soleus muscle of SD rats aged 92 weeks compared 
to that of rats aged 32 weeks (Fig 3). Plasma FFA and cholesterol increased as the rats 
aged (Fig 2). Alessio found that usual age-related physiological changes include increased 
blood cholesterol, increased body fat, decreased lean body mass, and loss of bone density 
[57]. In another study, serum cholesterol levels in SD rats increased sharply in 24 months 
(173 ± 85 mg/dL), and the levels of serum cholesterol was tended to increase with age in 
primates [58]. It is suggested that the aging process might contribute to the decline of 


































Effects of long-term taurine supplementation on age-related changes in 
Sprague-Dawley rats and analysis of the molecular mechanisms 











As an endogenous amino acid, taurine serves several physiological functions, the 
most primary being its role as an anti-fatigue molecule. Short-term taurine 
supplementation has the effect on exercise performance and duration. Administration of 
taurine (500 mg/kg BW) to mice after they had been running on a treadmill enhanced 
their recovery from endurance exercise-induced fatigue [23]. Administration of 3% 
taurine in drinking water for 1 month enhanced the exercise performance in rats, which 
correlated with the concentration of taurine in the muscle [24]. Oral administration of 
taurine (20, 100, and 500 mg/kg BW/day) to rats for 2 weeks improved exercise 
performance and duration, and maintained the concentration of taurine in the muscle [25]. 
Administration of taurine (500 mg/kg BW/day) to rats for 2 weeks maintained the levels 
of taurine in skeletal muscle during exercise and up-regulated physical endurance [26]. 
Taurine may be essential for skeletal muscle function and exercise capacity. Taurine 
deficiency in taurine transporter knockout (taut−/−) mice reduced the function of skeletal 
muscle [27]. Taurine depletion accelerates skeletal muscle aging and leads to early death 
in mice [28]. Taurine could improve the electrical and contractile properties of their 
muscle fibers [29]. It is reported by Miyazaki et al. that taurine affected skeletal muscle 
contraction and exercise performance by inhibiting oxidative stress, which alleviated both 
the increased levels of glutathione disulfide and the decreased concentration of taurine in 
the gastrocnemius (Gas) muscle, induced by exercise [25]. 
Given that taurine is associated with the function of skeletal muscle and exercise 
capacity as mentioned above, the effects of taurine on age-related changes are worth 
exploring. Numerous studies have been conducted on taurine administration in animal 
models. However, most of these have focused on induced animal taurine deficiency 
models (e.g., taurine transporter knockout, taurine antagonist, or dietary deficiency), 
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short-term taurine supplementation models, or supplementation of relatively high 
concentrations of taurine. Because taurine is commonly contained in various prepared 
beverages [16,59], we aimed to investigate the effects of a relatively low dose, long-term 
taurine administration on age-related changes in animal models. We hypothesized that 
long-term supplementation of taurine even at relatively lower concentrations may have 
improving effects on energy metabolism and skeletal muscle in aged rats via the function 
of AMP-activated protein kinase (AMPK). AMPK is a heterotrimeric protein kinase and 
has a function on the regulation of lipid metabolism [60], glucose uptake [61] in skeletal 
muscle, exercise performance [62, 63], and anti-aging [64]. Cheong and Chang reported 
that relatively lower concentration of taurine stimulates AMPK in L6 skeletal muscle cells 
[65]. Taurine may activate AMPK in skeletal muscle and have function on anti-aging 
effect through the function of AMPK. In this study, we examined the effects of long-term 
(5 months) administration of 0.5% (25 mg/kg/d) or 1% (50 mg/kg/d) taurine on changes 
in parameters, including VO2 consumption, spontaneous locomotor activity, taurine levels 
in tissues and plasma, phosphorylated AMPK, and its related gene and proteins 
expressions in skeletal muscles, with age. The evidence of this study could be of potential 




MATERIALS AND METHODS 
 
Materials 
Taurine, NaOH, trichloroacetic acid, perchloric acid, acetonitrile, o-phthalaldehyde 
(OPA), sodium tetra borate, formalin, 2-mercaptoethanol, 1% eosin Y solution, glucose 
commercial kit, MgCl2, sucrose, sodium fluoride, and α-tubulin antibody were purchased 
from Wako Pure Chemical Industries Ltd. (Osaka, Japan). KOH, ethanol, and nitro blue 
tetrazolium were purchased from Sigma-Aldrich (St. Louis, MO, USA). Rat L6 
myoblasts (JCRB9081) were purchased from JCRB Cell Bank (Osaka, Japan). 
Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS), and 0.02% 
ethylenediaminetetraacetic acid (EDTA) were purchased from MP Biomedicals (Santa 
Ana, CA, USA); penicillin, streptomycin, and 0.25% trypsin were from Invitrogen 
(Carlsbad, CA, USA). Hematoxylin from Merck KGaA (Darmstadt, Germany), and 
Mount-quick and Mount-quick aqueous from DAIDO SANGYO (Tokyo, Japan). 
Sepasol-RNA I Super G and sodium succinate were purchased from Nacalai Tesque 
(Kyoto, Japan). RNase inhibitor, ReverTra Ace® qPCR Master Mix, and gDNA remover 
kit were purchased from Toyobo Co., Ltd. (Osaka, Japan). KAPA SYBR® FAST qPCR 
kit was purchased from Kapa Biosystems (Wilmington, MA, USA). Antibodies against 
AMP-activated protein kinase α (AMPKα), phosphorylated AMPKα, and glucose 
transporter type 4 (GLUT4) were purchased from Cell Signaling Technology (Danvers, 
MA, USA). Antibodies against PGC-1α, myocyte enhancer factor 2A (MEF2A), and 
myoglobin were from Santa Cruz Biotechnology (CA, USA). 
 
Animal experiments 
All animal experiments were conducted in accordance with the guidelines of 
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Okayama Prefectural University and the laws and notifications of the Japanese 
government. All animal experiments were approved by the Animal Care and Use 
Committee of Okayama Prefectural University (protocol number 31-5). Male SD rats 
were obtained from Charles River Laboratories Japan, Inc. (Yokohama, Japan). They 
were housed individually in an air-conditioned room at 25 °C with an alternating 12 h 
light/dark cycle (light, 8:00–20:00). All the rats were allowed free access to commercial 
food (CE-2, CLEA Japan, Inc., Tokyo, Japan) and water. Food intake and body weight 
were measured daily. Respiratory metabolism was measured with an O2/CO2 metabolism 
measuring system (model MK-5000; Muromachi Kikai, Tokyo, Japan), and spontaneous 
locomotor activity was measured using an infrared sensor (PYS-001; Muromachi Kikai). 
Each rat was kept in a sealed chamber for 24 h. The airflow was maintained at 3.0 L/min 
and the temperature was 25 °C; the animals had free access to water and food.  
SD rats aged 32 weeks were assigned randomly to one of the following treatment 
groups: water (control), 0.5% taurine (w/v), or 1% taurine (w/v). The rats were fed a 
normal laboratory diet for 2 weeks for acclimatization, and were administered their 
respective doses from age 34 weeks, 5 d a week (5 mL/kg BW, n = 3–5/group), until 56 
weeks of age. The administered dose of taurine was 25 mg/kg body weight for the 0.5% 
taurine group and 50 mg/kg body weight for the 1% taurine group. Blood samples were 
collected at ages 33 (before administration), 37, 41, 45, 49, 53, and 56 weeks in 
heparinized tubes and centrifuged at 3,000 × g and 4 °C for 10 min and plasma was 
obtained. Respiratory metabolism and spontaneous locomotor activity were measured at 
33, 37, 41, 45, 49, and 53 weeks. At 56 weeks of age, the rats were anesthetized by 
intraperitoneal pentobarbital sodium injection (100 μL/100 g BW), and tissue samples 
were collected 24 h after the final treatment administration. Portions of the tissues were 
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frozen in liquid nitrogen and stored at -80 °C until the subsequent measurements. Other 
tissues were isolated, cramped, and freeze-dried (TOKYO RIKAKIKAI, Tokyo, Japan) 
for the measurement of taurine levels. 
 
Culture of L6 cells  
L6 myoblasts were grown to confluence in DMEM supplemented with 10% (v/v) FBS, 
100 units/mL penicillin, and 100 μg/mL streptomycin at 37 °C containing 5% CO2. Once 
myoblasts reached 80% confluence, differentiation of myotubes was induced by culturing 
them in a differentiation medium [DMEM containing 2% (v/v) horse serum]. Myotubes 
were harvested 11 d after differentiation, and experimental procedures were initiated. 
 
Biochemical analysis 
Freeze-dried tissue samples were homogenized with 2 mL of 0.5 N perchloric acid and 
centrifuged at 362 × g and 4 °C for 10 min (Pierno et al. 1998). The supernatant was 
neutralized with 5N and 1N of KOH, centrifuged at 362 × g at 4 °C for 10 min, and 
collected in a separate tube. Trichloroacetic acid 10% (v/v) was added to the precipitate 
the plasma proteins. The suspension of plasma samples was shaken for 1 h and 
centrifuged at 815 × g at 4 °C for 15 min and the supernatant was neutralized with 5N 
and 1N of KOH and collected. L6 myotubes were treated with 300 μM taurine for 60, 
120, 180, and 240 min, and the medium was collected. The pretreatment of the medium 
was the same as for plasma. Taurine was derivatized with OPA derivatizing reagent [200 
μL 25 mg/mL OPA in ethanol, 10 μL 2-mercaptoethanol, and 2.5 mL 0.1 M sodium 
tetraborate buffer (adjusted to pH 9.5 with NaOH)] and measured as a fluorescent adduct 
on an HPLC system (Waterfield 1994; Terrlink et al. 1994; Terrill et al. 2015). The HPLC 
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system (Shimadzu Corp., Tokyo, Japan) was equipped with LC-20AB HPLC pumps, a 
CTO-20A column oven, an SPD-M20A detector, and a reverse-phase column (Shim Pack 
VP-ODS separation, 250 L × 4.6; Shimadzu Corp., Tokyo, Japan). Phosphate buffer 
mixed with acetonitrile (70:30) was used as the mobile phase. The flow rate was 1 mL/min, 
the injection volume was 5 μL, the wavelength for detection was 338 nm, and the column 
temperature was 40 °C. Taurine was derivatized by mixing it with an equal volume of the 
OPA derivatizing reagent for 1 min before injecting the reaction mixture into the column 
(Ferreira et al. 1997). Plasma glucose level was measured using a commercial kit. SDH 
activity was measured by spectrophotometer (U-2900, Hitachi High-Tech Corp., Tokyo, 
Japan) (Spinazzi et al. 2012; Maruta and Yamashita 2020). Gas muscle was homogenized 
and added into reaction solution (25 mM potassium phosphate buffer (pH 7.5), 1 mg/ml 
bovine serum albumin, 300 μM potassium cyanide, 20 mM succinate and 80 μM DCPIP). 
The reaction mixture was incubated at 37˚C for 8 min, and plotted the baseline at 600nm 
for 2 min. The reaction was started by adding 50 μM DUB and was measured at 600 nm 
for 3 min. 
 
Histological analysis 
Gastrocnemius (Gas) muscle tissue was cut into 10-μm sections using a Leica 
CM3050 S cryostat (Leica Microsystems, Wetzlar, Germany) at -20 °C and fixed in 10% 
(v/v) formalin (Wako Pure Chemical Industries Ltd., Osaka, Japan). The sections were 
stained with hematoxylin and eosin (H&E) and mounted with Mount-Quick mounting 
medium. For SDH staining, Gas sections were air-dried at 20–25 °C for 5 min and 
incubated in a solution consisting of 50 mM phosphate buffer, 50 mM sodium succinate, 
and 0.5 mg/mL nitro blue tetrazolium at 37 °C for 40 min (Mangum et al. 2016). The 
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sections were washed in dH2O for 3 min and mounted with Mount-Quick aqueous 
mounting medium. Images were captured with a CCD camera (Olympus Optical, Tokyo, 
Japan) at ×100 magnification. 
 
qRT-PCR analysis 
Total RNA was isolated from frozen tissue samples with Sepasol-RNA I Super G. 
RNase inhibitor was added according to the manufacturer’s instructions. Total RNA was 
quantified, and cDNA was prepared using the ReverTra Ace® qPCR Master Mix and 
gDNA remover kit. Quantitative RT-PCR was performed on a StepOnePlus detection 
system (Applied Biosystems, Foster City, CA, USA) using the KAPA SYBR® FAST 
qPCR Master Mix Kit to determine the content of specific mRNAs. Data were normalized 
to β-actin mRNA, and the expression levels were compared to those for the water control 
group. The qRT-PCR primers used were as follows: rat β-actin (actb) forward: 5′-
GGAGATTACTGCCCTGGCTCCTA-3′, reverse: 5′-
GACTCATGTACTCCTGCTTGCTG-3′; rat PGC-1α (Ppargc1α) forward: 5′-
GACCCCAGAGTCACCAAATGA-3′, reverse: 5′-GGCCTGCAGTTCCAGAGAGT-3′; 
rat SDH forward: 5′-TGGGGCGACTCGTGGCTTTC-3′, reverse: 5′-
ATCTCCAGTTGTCCTCTTCCA-3′; rat cytochrome c (Cycs) forward: 5′-
ACCGGGACGTCTCCCTAAGA′, reverse: 5′-CTTCCGCCCAAACAGACCA-3′; rat 
MEF2A (Mef2a) forward: 5′-ATGAGAGGAACCGACAGGTG-3′, reverse: 5′-
TATCCGAGTTCGTCCTGCTT-3′; rat GLUT4 (Slc2a4) forward: 5′-
CTCATGGGCCTAGCCAATG-3′, reverse: 5′-GGGCGATTTCTCCCACATAC-3′. 
 
Western blot analysis 
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Tissue samples were homogenized in extraction buffer [25 mM Tris HCl [pH 8.0], 1 
mM EDTA, 0.5 mM dithiothreitol, 10 mM MgCl2, 0.25 mM sucrose, 50 mM sodium 
fluoride, and 1% (w/v) protease inhibitor] and centrifuged at 1,109 × g at 4 °C for 10 min. 
The protein content in the supernatant was determined using the Bradford assay. Aliquots 
containing ~30 μg protein were subjected to 10–15% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to an Immobilon-P 
membrane (Merck KGaA, Darmstadt, Germany). After blocking with 3% BSA/TBST, 
the membranes were incubated with primary antibodies overnight at 4 °C, washed thrice 
with TBST (Tris-buffered saline with Tween-20), and incubated with HRP-conjugated 
secondary antibodies for 60 min. For highly sensitive detection, the membranes were 
incubated with the primary antibodies, followed by biotin-conjugated secondary 
antibodies for 30 min, and then HRP-conjugated streptavidin for 15 min. The membranes 
were washed three times with TBST. The chemiluminescence reaction was performed for 
5 min with ImmunoStar LD (Wako Pure Chemical Industries) according to the 
manufacturer’s protocol. The chemiluminescent signals were visualized and quantified 
with ImageQuant LAS-4000 (Fujifilm, Tokyo, Japan). 
 
Statistical analysis 
Data are presented as means ± standard error (SE). Treatment means were subjected 
to one-way ANOVA followed by the Tukey–Kramer post-hoc test (Statcel 2, OMS Inc., 
Tokorozawa, Japan) or Dunnett’s multiple comparisons test (Ystat 2013, Igakushoin, 






Effect of taurine on body weight gain, respiratory metabolism, and spontaneous 
locomotor activity 
To examine the effect of taurine supplementation at relatively low dose on 
respiratory metabolism and spontaneous activity during aging, VO2 and spontaneous 
locomotor activity were measured for SD rats from 33 to 53 weeks of age. VO2 in the 
water group during the active period and the whole day period continuously decreased 
significantly every month as the rats aging, however, VO2 in the 0.5% and 1% taurine 
groups did not decrease significantly until 49 or 53 weeks (Fig 1A). In the resting period, 
VO2 of the water group significantly decreased from age 45 weeks, whereas that of the 
0.5% taurine group only decreased from 53 weeks, and that of the 1% taurine group did 
not decrease significantly as compared to rats aged 33 weeks. In the active and whole day 
periods, spontaneous locomotor activity of the water group decreased significantly every 
month as rats aged, whereas in the 0.5% taurine group, it started to decrease significantly 
from age 41 weeks (active period) and 45 weeks (the whole day). Additionally, in the 1% 
taurine group, the spontaneous locomotor activity did not decrease significantly until 49 
weeks (both in the active and the whole day periods) relative to that at the age of 33 weeks 
(Fig 1B). With increasing age, the spontaneous locomotor activity in the water group 
during the resting period decreased significantly at the age of 53 weeks, whereas in the 
taurine groups, no significant change was observed. The body weight gain increased 
steadily as rats aging; there was no significant difference in the water and taurine groups 





















Fig 1. VO2 in SD rats from 33 to 53 weeks of age in the resting, active, and whole day 
periods (a). Spontaneous locomotor activity of SD rats from 33 to 53 weeks of age in the 
resting, active, and whole day periods (b). Average body weight gain of SD rats from 34 
to 55 weeks of age (c). Values shown represent means ± SE for 5 rats. *p <0.05, **p <0.01 
statistically significant versus the value obtained at 33 weeks of age. Results were 





Taurine levels in plasma and tissues, taurine incorporation into L6 myotube cells, and 
the effect of taurine on plasma glucose level 
Taurine levels in plasma and tissues containing skeletal muscles were measured to 
examine the effect of long-term of low dose taurine supplementation on the incorporation 
of taurine to tissues. Plasma taurine levels (µM) in the 0.5% and 1% taurine groups were 












Fig 2. Plasma taurine level (µM) in SD rats from 33 to 53 weeks of age in the water, 0.5% 
taurine, and 1% taurine groups (a). Values shown represent means ± SE for 5 rats. *p 
<0.05, **p <0.01 statistically significant versus the value obtained in the water group. 
Taurine incorporation (µM) into L6 cells, 60, 120, 180, and 240 min after treatment with 
300 µM taurine (b). Values shown represent means ± SE for 4–5. *p <0.05, **p <0.01 
statistically significant versus the values after 60 min in the treatment group. Results were 
analyzed using Dunnett’s test 
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To determine the taurine uptake by the skeletal muscle tissue, taurine incorporation 
into L6 myotube cells was measured. Treatment with taurine (300 µM) for 120, 180, and 
240 min increased the incorporation of taurine into L6 cells in a time-dependent manner 
(Fig 2B). The level of taurine was measured in the Gas muscle, extensor digitorum longus 
(EDL) muscle, soleus muscle, intestine, liver, and kidney in 24 h after administration of 
taurine. Twenty-one week after administration, at the age of 56 weeks, the level of taurine 
(µmol/g) in the 1% taurine group was the highest in the kidney and intestine among the 










Fig 3. Taurine content (µmol/g) in gastrocnemius (Gas) muscle, extensor digitorum 
longus (EDL) muscle, soleus muscle, intestine, liver, and kidney of Sprague-Dawley (SD) 
rats at 56 weeks of age in the water, 0.5% taurine, and 1% taurine groups in 24 hr after 
the taurine administration. Values shown represent means ± SE for 5 rats. *p <0.05, **p 
<0.01 statistically significant versus the values in the water group. Results were analyzed 




There were no changes in taurine levels in skeletal muscles and liver among water 
and taurine groups. To examine the glucose lowering effect of taurine during aging 
process, glucose level was measured. The level of glucose (mg/dL) in the plasma was 
significantly lower in the 0.5% and 1% taurine groups than in the water group at 56 weeks 









Fig 4. Plasma glucose levels in SD rats at 33 to 56 weeks of age in the water, 0.5% taurine, 
and 1% taurine groups. Values shown represent means ± SE for 5 rats. *p <0.05, **p 
<0.01 statistically significant versus the value in the water group. Results were analyzed 
using Dunnett’s test 
 
Effect of taurine on phosphorylated AMPK and genes and proteins related with skeletal 
muscle function 
To examine the effect of long-term administration of taurine on modulation of 
molecules related to energy metabolism in skeletal muscle, the phosphorylation of AMPK 
in soleus and Gas muscles was determined. Phosphorylated AMPK in soleus muscle 
tended to increase in both taurine groups. In Gas muscle, the level of phosphorylated 
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Fig 5. Effect of taurine administration on the phosphorylation of AMPK in soleus and 
Gas muscles of SD rats. Values shown represent means ± SE for 3–5 rats. **p <0.01 








Fig 6. Effect of taurine administration on relative mRNA expression of Ppargc1α, SDH, 
Cycs, Mef2a, and Slc2a4 in the soleus muscle of SD rats at 56 weeks of age (a). Effect of 
taurine administration on relative mRNA expression of Ppargc1α, SDH, Cycs, Mef2a, 
and Slc2a4 in Gas muscle of SD rats at 56 weeks of age (b). Values shown represent 
means ± SE for 3–5 rats. *p <0.05, **p <0.01 statistically significant versus the values in 












Fig 7. Effect of taurine administration on relative levels of MEF2A, PGC-1α, GLUT4, 
and myoglobin in the soleus muscle of SD rats(a). Effect of taurine administration on the 
relative levels of MEF2A, PGC-1α, GLUT4, and myoglobin in the Gas muscle of SD rats 
(b). Values shown represent means ± SE for 3–5 rats. *p <0.05, **p <0.01 statistically 
significant versus the values in the water group. Results were analyzed using Dunnett’s 
test 
 
Expression levels of Ppargc1α, SDH, Cycs, and Mef2a mRNAs in the soleus muscle 
were significantly increased in the 0.5% taurine group compared to that in the water group 
(Fig 6A). The expression of Mef2a mRNA was also significantly upregulated in the 1% 
taurine group relative to that in the water group. In Gas muscle, mRNA expression levels 
of SDH, Mef2a, and Slc2a4 were significantly increased in the 0.5% taurine group. The 
expression levels of Cycs and Slc2a4 mRNAs were significantly enhanced in the 1% 
taurine group and both taurine groups, respectively, compared with that in the water group 
(Fig 6B). Protein level of MEF2A was significantly increased in the soleus muscle in both 
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taurine groups (Fig 7A) and 1% taurine group in the Gas muscle (Fig 7B). The level of 
GLUT4 protein in Gas muscle was increased significantly in the 1% taurine group and 
tended to be increased in 0.5% taurine group. 
 
Histological analysis 
The SDH staining was performed to characterize the mitochondrial enzyme function 
and the oxidative capacity of myofibers (Mangum et al. 2016; White et al. 2011). Fig. 8 
shows H&E and SDH staining and SDH activity of Gas muscle. Gas muscle of rats 
expressed higher in SDH protein by taurine supplementation and showed significantly 










Fig 8. Representative H&E and SDH staining of Gas muscle sections from SD rats in the 
water, 0.5% taurine, and 1% taurine groups at 56 weeks of age (a). Magnification: ×100. 
Scale bar, 500 μm. SDH activity in Gas muscle of SD rats in the water, 0.5% taurine, and 






As shown in Fig. 1A, VO2 in the water group during the active and whole day periods 
decreased significantly every month as the rats aging, which was consistent with the result 
in Chapter Ⅱ. In contrast, VO2 in the 0.5% and 1% taurine groups did not decrease 
significantly until 49 or 53 weeks of age. This indicates that long-term and relatively low 
dose of taurine could attenuate the age-related changes in O2 consumption. In the same 
way, as shown in Fig. 1B, during the active and whole day periods, the spontaneous 
locomotor activity of rats in the water group decreased significantly every month, 
however, in the 0.5% taurine group, significant decrease was observed 1 or 2 months later 
than in the water group, and it did not decrease significantly in the 1% taurine group until 
49 weeks of age. This suggests that long-term administration of taurine at relatively low 
dose could attenuate the age-related change in the spontaneous locomotor activity.  
Plasma taurine levels were significantly higher in the 0.5% and 1% taurine groups 
than in the water group at 37, 41, and 53 weeks of age (Fig 2A). There was no significant 
change in taurine level among groups in each skeletal muscle after the long-term 
administration of taurine. Sved et al. reported the concentration of taurine in plasma and 
tissues after dosing in rats receiving 1, 7, or 14 days of taurine at 30 or 300 mg/kg/day 
[66]. They describe that overall the concentrations in the different tissues containing 
muscle did not show major differences between controls and treated animals, and were 
not greatly influenced by dose level or duration of treatment. They discuss that exogenous 
taurine rapidly equilibrates with endogenous body pools and that any excess is rapidly 
eliminated by the kidneys. However, from the results of taurine incorporation into L6 
cells in this study, taurine supplementation might promote the incorporation of taurine 
into skeletal muscles, which might have an effect on the physiological functions. Taurine 
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supplementation of 1% stimulated phosphorylation of AMPK significantly and 0.5% 
taurine supplementation tended to stimulate the phosphorylation in Gas muscle (Fig 5). 
AMPK plays a key role in the regulation of energy metabolism [54, 60, 67], oxidative 
capacity [68], exercise capacity [62, 63], and aging processes [64]. AMPK also has a role 
in stimulation of glucose uptake in skeletal muscle [61] by induction of primary glucose 
transporter, GLUT4 gene via HDAC4/5-MEF2 axis, in which the transcription of GLUT4 
gene is modulated by MEF2A, a member of the MEF2 family of transcription factors, 
and the transcriptional activity of MEF2A is enhanced by AMPK via its inhibiting action 
for HDAC4/5, which is transcriptional repressor of MEF2 proteins [6, 69]. Moreover, 
AMPK has an inducing effect on the expression of MEF2A [70, 71]. In the present study, 
plasma glucose levels in the 0.5% and 1 % taurine groups were significantly lower at 56 
weeks than in the water group (Fig 4). And the expressions of GLUT4 gene and protein 
were significantly induced in the Gas muscle of rats in the 1% taurine group (Fig 6B and 
7B). In 0.5% taurine group, it shows a significant increase of GLUT4 gene and an increase 
tendency of GLUT4 protein in Gas muscle (Fig 6B and 7B). Furthermore, the expression 
of MFE2A protein was significantly increased in 1% taurine group in Gas muscle (Fig 
7B). Taurine group of 0.5% shows significant increases in MEF2A gene and protein in 
Gas muscle (Fig 6B and 7B). These results indicate that taurine supplementation might 
contribute to increase glucose uptake in skeletal muscle cells and lower plasma glucose 
levels through the induction of MEF2A and GLUT4 via the function of AMPK. Other 
studies show that taurine supplementation could normalize blood glucose and plasma 
insulin levels in CHT male C57BL/6J mice [72], or glucose supplementation following 
the administration of taurine significantly decreased the blood glucose levels in male 















Fig 9. Analysis of the molecular mechanisms of taurine effect in skeletal muscle 
 
Aging is associated with dysregulation of energy metabolism and mitochondrial 
dysfunction. SDH activity is a performance of mitochondrial oxidative capacity [45, 46]. 
Comparison between young and old rats showed that SDH activity decreases in the 
muscles of old rats [47]. SDH gene expression in the soleus and Gas muscles of taurine 
groups tended to be higher than that in the water group (Fig 6). SDH activity in Gas 
muscle also result significantly higher in both taurine groups (Fig. 8). Cytochrome c is 
essential for energy production and mitochondrial respiration, as a component of the 
electron transport chain and mitochondrial markers [54, 55]. Taurine supplementation 
increased Cycs mRNA expression levels in the soleus muscle of the 0.5% taurine group 
and in the Gas muscle of 1% taurine group compared to that in the water group. These 
40 
 
indicate that supplementation of taurine might improve the age-related decline in 
mitochondrial oxidative capacity. PGC-1α plays a key role in the regulation of 
mitochondrial biogenesis and oxidative metabolism, its activity is regulated by AMPK 
[74-76], and it is mutually activated with MEF2A [77]. In this study, the expression of 
PGC-1α protein tended to be increased in Gas muscle of 1% taurine group (Fig 7B). 
Cytochrome c and GLUT4 genes were increased significantly in 1% taurine group (Fig 
6B). And SDH activity was also increased in taurine groups (Fig 8). AMPK may increase 
the expression of PGC-1α in the muscle by 1% taurine supplementation, lead to increased 
MEF2A gene as well as elevate the levels of cytochrome c, SDH, and GLUT4 genes, 
which are a subset of genes regulated by PGC-1α [50, 78]. All these factors are associated 
with the function of mitochondria and skeletal muscle, and it is indicated that the function 
of skeletal muscle would be improved by long-term taurine supplementation at relatively 
low dose during aging process. The potential mechanisms of taurine effect in skeletal 
muscle is shown in Fig 9. In this study, taurine supplementation might phosphorylate and 
activate AMPK, and increased mitochondria function by SDH and Cycs, which might be 
mediated by PGC-1α. In addition, taurine supplementation increased MEF2A and 
GLUT4 mediated by AMPK, and elevate skeletal muscle function. This may be the 




































Aging process might contribute to a decline in the O2 consumption, spontaneous 
locomotor activity, and glucose oxidation of rats aged 90 weeks compared to that of rats 
aged 32 weeks. With advancing age, skeletal muscle mass decreased significantly in rats 
aged 85 weeks, and 92 weeks compared to that in rats aged 32 weeks. With aging, the 
levels of genes Myh7, Ppargc1α, Cycs, and sdha, and mitochondrial DNA, which are 
related to skeletal muscle function and muscle oxidative capacity, decreased significantly 
in the soleus muscle of rats aged 85 and 92 weeks compared to that of rats aged 32 weeks. 
In addition, lipid accumulation in skeletal muscle and weight of white adipose tissue 
(WAT) around kidney increased with age in rats. 
Long-term administration of taurine could attenuate the age-related decline in O2 
consumption and spontaneous locomotor activity. Taurine might modulate age-related 
changes in respiratory metabolism and skeletal muscle function via PGC-1α, SDH, Cycs, 
MEF2A, glucose transporter 4 (GLUT4), and myoglobin, which are regulated by the 
activation of AMP-activated protein kinase (AMPK). This study contributes to the further 
understanding of age-related changes and examines of the mechanism underlying the 
effects of taurine on age-related changes, which may have potential clinical implications. 
As an endogenous amino acid, taurine may be an ideal treatment for daily intake or for 
further testing in clinical trials. A more extensive investigation on skeletal muscle cells, 
animal models, or human models is needed to further explore its potential application in 
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